PE20090225A1 - Proteinas de fusion que degradan el peptido beta amiloide - Google Patents

Proteinas de fusion que degradan el peptido beta amiloide

Info

Publication number
PE20090225A1
PE20090225A1 PE2008000557A PE2008000557A PE20090225A1 PE 20090225 A1 PE20090225 A1 PE 20090225A1 PE 2008000557 A PE2008000557 A PE 2008000557A PE 2008000557 A PE2008000557 A PE 2008000557A PE 20090225 A1 PE20090225 A1 PE 20090225A1
Authority
PE
Peru
Prior art keywords
fusion proteins
amyloid peptide
beta amyloid
fusion protein
peptide
Prior art date
Application number
PE2008000557A
Other languages
English (en)
Inventor
Christin Andersson
Per-Ola Freskgard
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of PE20090225A1 publication Critical patent/PE20090225A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

REFERIDA A UNA PROTEINA DE FUSION DE FORMULA M-A, DONDE M ES UN COMPONENTE PROTEICO QUE PROLONGA LA VIDA MEDIA DE LA PROTEINA DE FUSION TAL COMO UNA PARTE Fc DE UN ANTICUERPO IgG2 Y A ES UN COMPONENTE PROTEICO QUE CORTA EL PEPTIDO BETA AMILOIDE TAL COMO NEPRILISINA EXTRACELULAR QUE TIENE UNA SECUENCIA DE AMINOACIDOS DE SEQ ID N‘ 1,2,3 O 4 Y DONDE DICHOS M Y A ESTAN UNIDOS POR UN CONECTOR L TAL COMO UN PEPTIDO O UN CONECTOR QUIMICO. DICHA PROTEINA DE FUSION CORTA EL PEPTIDO BETA AMILOIDE Y ES UTIL EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER
PE2008000557A 2007-03-28 2008-03-27 Proteinas de fusion que degradan el peptido beta amiloide PE20090225A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US90847107P 2007-03-28 2007-03-28

Publications (1)

Publication Number Publication Date
PE20090225A1 true PE20090225A1 (es) 2009-04-19

Family

ID=39788753

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000557A PE20090225A1 (es) 2007-03-28 2008-03-27 Proteinas de fusion que degradan el peptido beta amiloide

Country Status (12)

Country Link
US (1) US20080242590A1 (es)
EP (1) EP2139525A4 (es)
JP (1) JP2010522559A (es)
CN (1) CN101668545A (es)
AR (1) AR066199A1 (es)
AU (1) AU2008230177B2 (es)
CA (1) CA2681404A1 (es)
CL (1) CL2008000910A1 (es)
PE (1) PE20090225A1 (es)
TW (1) TW200907056A (es)
UY (1) UY30984A1 (es)
WO (1) WO2008118093A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2765688A1 (en) * 2009-06-19 2010-12-23 Medimmune, Llc Protease variants
WO2011161127A1 (en) 2010-06-21 2011-12-29 Medimmune, Llc Protease variants of human neprilysin
WO2011160732A1 (en) 2010-06-21 2011-12-29 Medimmune, Llc. Protease variants of human neprilysin
US20140377319A1 (en) * 2011-04-21 2014-12-25 Washington University Altering protein concentrations in cerebrospinal fluid and/or brain interstitial fluid
CN103529182B (zh) * 2012-07-06 2016-03-16 中国科学院上海生命科学研究院 rbo/Efr3a/Efr3b基因或其蛋白在诊断和治疗阿尔茨海默病中的应用
EP2832854A1 (en) * 2013-08-02 2015-02-04 F. Hoffmann-La Roche AG Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin
AU2014298519A1 (en) * 2013-08-02 2016-02-04 F. Hoffmann-La Roche Ag Therapeutic fusion protein
EP3783364A3 (en) * 2014-05-22 2021-05-19 Shimadzu Corporation Surrogate biomarker for evaluating intracerebral amyloid beta peptide accumulation and method for analysis thereof
EP3444264A4 (en) * 2016-04-14 2020-03-18 TAO Health Life Pharma Co., Ltd. PEPTIDE FOR AMYLOSPHEROID BINDING INHIBITION (ASPD), AND ASSESSMENT AND SCREENING METHOD
KR102676279B1 (ko) * 2017-01-30 2024-06-20 내션얼 리서치 카운슬 오브 캐나다 혈액-뇌 장벽을 관통이동하는 화합물 및 이의 용도
EP3604328A4 (en) 2017-03-23 2021-01-06 Hanmi Pharm. Co., Ltd. REDUCED INSULIN ANALOGUE COMPLEX FOR INSULIN RECEPTOR AND ITS USE
CN110241128B (zh) * 2018-03-07 2020-10-02 上海大学 一种含有cbd的融合基因、细胞系、液态ecm与应用
CA3107349A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
WO2020023418A1 (en) 2018-07-23 2020-01-30 Enclear Therapies, Inc. Methods of treating neurological disorders
EP3952947A4 (en) 2019-04-11 2024-07-03 Enclear Therapies Inc METHODS FOR IMPROVING CEREBRAL SPINAL FLUID AND DEVICES AND SYSTEMS THEREFOR

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
AU758240B2 (en) * 1998-02-25 2003-03-20 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US20020086405A1 (en) * 2000-09-25 2002-07-04 Inmaculada Silos-Santiago 56638, a novel human neprilysin protease and uses thereof
CA2260376A1 (en) * 1999-02-11 2000-08-11 Universite De Montreal New metalloproteases of the neprilysin family
US20030083277A1 (en) * 2000-02-24 2003-05-01 Hersh Louis B. Use of insulin degrading enzyme (IDE) for the treatment of alzheimer's disease in patients
WO2002096460A1 (en) * 2001-05-30 2002-12-05 Cornell Research Foundation, Inc. Endopeptidase/anti-psma antibody fusion proteins for treatment of cancer
US20050118632A1 (en) * 2003-11-06 2005-06-02 Jian Chen Polynucleotides and polypeptides encoding a novel metalloprotease, Protease-40b
EP1934341A1 (en) * 2005-10-03 2008-06-25 AstraZeneca AB Fusion proteins having a modulated half-life in plasma

Also Published As

Publication number Publication date
EP2139525A1 (en) 2010-01-06
CL2008000910A1 (es) 2008-11-21
AR066199A1 (es) 2009-08-05
EP2139525A4 (en) 2010-08-18
US20080242590A1 (en) 2008-10-02
WO2008118093A1 (en) 2008-10-02
UY30984A1 (es) 2008-10-31
AU2008230177B2 (en) 2012-05-10
CN101668545A (zh) 2010-03-10
AU2008230177A1 (en) 2008-10-02
CA2681404A1 (en) 2008-10-02
JP2010522559A (ja) 2010-07-08
TW200907056A (en) 2009-02-16

Similar Documents

Publication Publication Date Title
PE20090225A1 (es) Proteinas de fusion que degradan el peptido beta amiloide
Haney et al. Peptide design for antimicrobial and immunomodulatory applications
UY31123A1 (es) Proteinas de fusion natriureticas
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
DK1761553T3 (da) MHC molecule-binding tumor-associated peptides
PE20131334A1 (es) Anticuerpo igg1 humanizado
NO20063026L (no) Antistoffer
ATE527353T1 (de) Pdgf-bindendes polypeptid aus protein a
CL2011003122A1 (es) Anticuerpo que se une a la proteina tau fosforilada en la serina 422 (tau ps422), pero no se une a la tau ni al fragmento mcak fosforilado; acido nucleico que lo codifica; metodo de produccion; composicion farmaceutica; y uso util en el tratamiento de una tauopatia, tal como la enfermedad de alzheimer.
PE20171325A1 (es) Polipeptidos del receptor de activina variante y uso de los mismos
PE20090711A1 (es) Region constante de anticuerpo mutante
AR062030A1 (es) Proteinas de fusion de exendina
NO20071419L (no) Polypeptidvarianter med endret effektorfunksjon
NZ597692A (en) Anti-IGF antibodies
DE602005008996D1 (de) Radiofluorierte peptide
PL397167A1 (pl) Przeciwnowotworowe bialko fuzyjne
EA201390820A1 (ru) Слитый белок против рака
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
WO2007018619A3 (en) Chimeric therapeutic agents
DK2007885T3 (da) Fremgangsmåde til forøgelse af in vivo-genvindingen af terapeutiske polypeptider
WO2008033395A3 (en) Melanocortin and transferrin fusion proteins
DE602007004110D1 (de) Hausstaubmilbenallergen
MX2017010359A (es) Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc).

Legal Events

Date Code Title Description
FD Application declared void or lapsed